# EDGAR Filing Document

**Accession Number:** 0001040130
**File Stem:** 0001040130-25-000091
**Filing Date:** 2025-11
**Character Count:** 40558
**Document Hash:** d6fc0ba566e6a870745313e233676d92
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001040130-25-000091.hdr.sgml**: 20251126

**ACCESSION NUMBER**: 0001040130-25-000091

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20251126

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20251126

**DATE AS OF CHANGE**: 20251126

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PETMED EXPRESS INC
- **CENTRAL INDEX KEY:** 0001040130
- **STANDARD INDUSTRIAL CLASSIFICATION:** RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 650680967
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42429
- **FILM NUMBER:** 251530222

**BUSINESS ADDRESS:**
- **STREET 1:** 420 SOUTH CONGRESS AVENUE
- **CITY:** DELRAY BEACH
- **STATE:** FL
- **ZIP:** 33445
- **BUSINESS PHONE:** (561) 426-4444

**MAIL ADDRESS:**
- **STREET 1:** 420 SOUTH CONGRESS AVENUE
- **CITY:** DELRAY BEACH
- **STATE:** FL
- **ZIP:** 33445

?xml version='1.0' encoding='ASCII'? pets-20251126

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): November 26, 2025

**<u>PetMed Express, Inc.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Florida** | **000-28827** | **65-0680967** |
| (State or other jurisdiction<br>of incorporation) | (Commission<br>File Number) | (I.R.S. Employer<br>Identification No.) |

---

**<u>420 South Congress Avenue, Delray Beach, Florida 33445</u>**

(Address of principal executive offices) (Zip Code)

**<u>(561) 526-4444</u>**

(Registrant's telephone number, including area code)

**<u>Not Applicable</u>**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $.001 per share | PETS | NASDAQ |
| Preferred Stock Purchase Rights | N/A | NASDAQ |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company □

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. □

------

**Item 1.01. Entry Into a Material Agreement**

On November 26, 2025, PetMed Express, Inc., a Florida corporation (the "<u>Company</u>"), entered into Amendment No. 1 (the "<u>Amendment</u>") to the Rights Agreement, dated as of December 3, 2024, by and between the Company and Continental Stock Transfer & Trust Company, a federally chartered trust company, as rights agent (the "<u>Original Rights Agreement</u>," and as amended by the Amendment, the "<u>Amended Rights Agreement</u>"). Pursuant to the Amendment, the Final Expiration Date of the Rights has been extended until the Close of Business on December 2, 2026. Capitalized terms used but not defined herein have the meanings specified in the Amended Rights Agreement.

The Rights are in all respects subject to and governed by the provisions of the Amended Rights Agreement. The above description of the Original Rights Agreement and the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Original Rights Agreement, which is incorporated by reference to Exhibit 4.1 to the Form 8-K/A filed by the Company with the U.S. Securities and Exchange Commission (the "<u>SEC</u>") on December 18, 2024, and to the Amendment, which is attached hereto as Exhibit 4.2, both of which are incorporated herein by reference.

**Item 3.03. Material Modifications to Rights of Security Holders.**

The information set forth under Item 1.01 is incorporated into this Item 3.03 by reference.

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On November 26, 2025, the Board unanimously approved, upon the recommendation of the Board's Compensation and Human Capital Committee, an increase in the annual base salary of Douglas Krulik, the Company's Interim Principal Financial Officer and Chief Accounting Officer, from $300,000 to $330,000 per year, with such increase being deemed to be effective as of August 30, 2025. On the same day, upon approval by the Board upon the recommendation of the Compensation and Human Capital Committee, the Company also entered into a Change of Control and General Severance Agreement with Mr. Krulik (the "<u>CCGS Agreement</u>").

The CCGS Agreement provides that, in the event that Mr. Krulik's employment is terminated by the Company at any time without "Cause" (whether or not a Change of Control has occurred), Mr. Krulik will be entitled to severance compensation equal to six months of his annual base salary as then in effect in exchange for a customary full release of claims, which severance shall be paid over a six-month period after termination. The agreement further provides that, in the event that Mr. Krulik's employment is terminated by the Company without Cause during the twelve-month period following a Change of Control or in the event that Mr. Krulik resigns for "Good Reason" during such twelve-month period, then (i) Mr. Krulik will be entitled to severance compensation equal to six months of his annual base salary as then in effect in exchange for a customary full release of claims, which severance shall be paid over a six-month period after termination, and (ii) all unvested restricted stock awards and vested restricted units then held by Mr. Krulik will immediately become vested upon such termination.

For purposes of the CCGS Agreement, the term "Change of Control" has the meaning set forth in the Company's 2024 Omnibus Incentive Plan. The term "Cause" is customarily defined to include commission of willful dishonesty, commission of a felony or other crime involving fraud and dishonesty, personal misconduct or negligent conduct that injures the interests of the Company, and various similar acts, all as more particularly defined in CCGS Agreement. "Good Reason" includes certain material adverse changes in Ms. Krulik's duties, responsibilities, functions or title with the Company or a material reduction in Mr. Krulik's base salary, as more particularly defined in the Employment Agreement.

The foregoing does not purport to be a complete description of the CCGS Agreement and is qualified in its entirety by reference to the full text of such agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 8.01. Other Events.**

On November 26, 2025, the Company issued a press release, which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

------

**Item 9.01 Financial Statements and Exhibits.**

(d)Exhibits

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 4.1 | <u>[Rights Agreement, dated as of December 3, 2024, by and between PetMed Express, Inc. and Continental Stock Transfer & Trust Company, as rights agent (incorporated by reference to Exhibit 4.1 to Form 8-K/A filed with the SEC on December 18, 2024)](https://www.sec.gov/Archives/edgar/data/1040130/000104013024000126/pets-shareholderrightsagre.htm)</u> |
| 4.2 | <u>[Amendment No. 1 to Rights Agreement, dated as of November 26, 2025, by and between PetMed Express, Inc. and Continental Stock Transfer & Trust Company, as rights agent](exhibit42amendmentno1torig.htm)</u> |
| 10.1 | <u>[Change of Control and General Severance Agreement, dated November 26, 2025, between PetMed Express, Inc. and Douglas Krulik](exhibit101changeofcontrola.htm)</u> |
| 99.1 | <u>[Press release](exhibit991pressrelease.htm)[issued by PetMed Express,](exhibit991pressrelease.htm)[Inc. on November 26, 2025](exhibit991pressrelease.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 26, 2025

---

| | |
|:---|:---|
| PETMED EXPRESS, INC. | PETMED EXPRESS, INC. |
| By: | /s/ Robert Lawsky |
| Name: | Robert Lawsky |
| Title: | General Counsel |

---

## Exhibit 4.2

**AMENDMENT NO. 1 TO RIGHTS AGREEMENT**

This Amendment No. 1, dated as of November 26, 2025 (this "**Amendment**"), amends that certain Rights Agreement, dated as of December 3, 2024 (the "**Rights Agreement**"), by and between PetMed Express, Inc., a Florida corporation (the "**Company**"), and Continental Stock Transfer & Trust Company, a federally chartered trust company (the "**Rights Agent**"). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the Rights Agreement.

**WHEREAS**, the Company and the Rights Agent have executed and entered into the Rights Agreement;

**WHEREAS**, Section 27 of the Rights Agreement provides, among other things, that, for so long as the Rights are then redeemable, the Company may, in its sole and absolute discretion, and the Rights Agent shall, if the Company so directs, supplement or amend any provision of the Rights Agreement in any respect without the approval of any holders of Rights or Common Shares, and the Rights Agent shall, if the Company so directs, execute such supplement or amendment.;

**WHEREAS**, to the knowledge of the Company, as of the date hereof, the Rights are still redeemable;

**WHEREAS**, the Board of Directors of the Company has (i) deemed it advisable and in the best interests of the Company and its stockholders to amend certain provisions of the Rights Agreement as set forth herein; (ii) approved this Amendment; and (iii) authorized the proper officers of the Company to execute and deliver the same to the Rights Agent;

**WHEREAS**, pursuant to and in accordance with Section 27 of the Rights Agreement, the Company desires to amend the Rights Agreement as set forth below.

**NOW, THEREFORE**, in consideration of the premises set forth above, the parties hereto, intending to be legally bound hereby, agree as follows

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.The definition of "Final Expiration Date" set forth in Section 7(a) of the Rights Agreement is hereby amended and restated in its entirety as follows:

"**Final Expiration Date**" shall mean the Close of Business on December 2, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.Exhibits B and C to the Rights Agreement shall be deemed amended in a manner consistent with this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.This Amendment shall be deemed to be a contract made under the laws of the State of Florida and for all purposes shall be governed by and construed in accordance with the laws of such State applicable to contracts to be made and performed entirely within such State, without giving effect to the choice of law or conflict of law principles thereof or of any other jurisdiction to the extent that such principles would require or permit the application of the laws of another jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.If any term, provision, covenant, or restriction of this Amendment, or the application thereof to any circumstance, is held by a court of competent jurisdiction or other authority to be invalid, null, void, or unenforceable, the remainder of the terms, provisions, covenants, and restrictions of this Amendment shall remain in full force and effect and shall in no way be affected, impaired, or invalidated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.Except as expressly set forth in this Amendment, the Rights Agreement will not otherwise be supplemented or amended by virtue of this Amendment and will remain in full force and effect and otherwise shall be unaffected by virtue of this Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.This Amendment may be executed in any number of counterparts, and each of such counterparts shall for all purposes be deemed to be an original, and all such counterparts shall together constitute but one and the same

------

instrument. A signature to this Amendment executed and/or transmitted electronically shall have the same authority, effect, and enforceability as an original signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.This Amendment shall be effective as of the date first written above,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.Upon and after the effectiveness of this Amendment, each reference in the Rights Agreement to "this Agreement," "hereunder," "hereof" or words of like import referring to the Rights Agreement, and each reference in any other document to "the Rights Agreement," "thereunder," "thereof" or words of like import referring to the Rights Agreement, shall mean and be a reference to the Rights Agreement as amended hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.The undersigned officer of the Company, being duly authorized on behalf of the Company, hereby certifies in his or her capacity as an officer on behalf of the Company to the Rights Agent that this Amendment is in compliance with the terms of Section 27 of the Rights Agreement.

[*Signature Page Follows*]

------

**IN WITNESS WHEREOF,** this Amendment has been duly executed by the Company and the Rights Agent as of the date first written above.

**PETMED EXPRESS, INC.**

<u>By: /s/ Leslie C.G. Campbell</u>

Name: Leslie C.G. Campbell

Title: Interim CEO

**CONTINENTIAL STOCK TRANSFER & TRUST COMPANY**

<u>By: /s/ Erika Young</u>

Name: Erika Young&nbsp;&nbsp;&nbsp;&nbsp;

Title: Vice President

## Exhibit 10.1

**CHANGE OF CONTROL AND GENERAL SEVERANCE AGREEMENT**

This Change of Control and General Severance Agreement (this "***Agreement***"), dated November 26, 2025 (the "***Effective Date***"), is entered into by and between PetMed Express, Inc., a Florida corporation (the "***Company***"), and Douglas Krulik (the "***Employee***").

**<u>W</u> <u>I</u> <u>T</u> <u>N</u> <u>E</u> <u>S</u> <u>S</u> <u>E</u> <u>T</u> <u>H</u>**

**WHEREAS**, The Employee currently serves as the Chief Accounting Officer and Interim Principal Financial Officer of the Company; and

**WHEREAS**, The Board of Directors of the Company (the "***Board***") has determined that, in order to induce the Employee to continue to serve as a key employee of the Company, it is advisable and in the best interest of the Company and its shareholders to provide the Employee with certain compensation in the event the Employee's employment with the Company is terminated under certain circumstances and to provide certain protections in the event of a change of control of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **NOW, THEREFORE,** in consideration of the foregoing and the mutual covenants contained herein, the Company and the Employee agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Section 1. <u>Definitions</u>**. Capitalized terms used herein and not otherwise defined herein shall have the meanings given to them in ***<u>Annex A</u>*** attached hereto, except where the context requires otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Section 2. <u>Term of Agreement</u>**. This Agreement shall be effective as of the Effective Date and shall continue in effect until the termination of the Employee's employment or upon mutual written agreement of the Employee and the Company. For the avoidance of doubt, the Employee's and Company's obligations hereunder that are intended to survive the Employee's termination of employment shall nonetheless be enforceable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Section 3. <u>At Will Employment; Reasons for Termination</u>**. The Employee's employment shall continue to be at-will, as defined under applicable law. If the Employee's employment terminates for any reason or no reason, the Employee shall not be entitled to any compensation, benefits, damages, awards or other payments in respect of such termination, except as expressly provided in this Agreement or pursuant to the terms of any Applicable Benefit Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Section 4. <u>General Benefits Upon Separation; Release</u>**.

&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Compensation</u>. Notwithstanding anything to the contrary herein, upon the Employee's termination of employment for any reason, the Employee (or his estate) shall be entitled to any and all compensation, benefits, awards and other payments that are legally required by any Applicable Benefit Plan, the COBRA Act, or other applicable law, after taking into account the agreements set forth herein.

&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>No Payments Without Release</u>. The Employee shall not be entitled to any of the compensation (other than Accrued Compensation), benefits or other payments provided herein in respect of the termination of his employment, unless and until he has provided to the Company a full release of claims in the form provided by the Company (the "***Release***"), which release shall be dated not earlier than the date of the termination of Employee's employment, which release shall be provided to the Employee within 9 days of the Employee's Date of Termination and executed within 30 days of the Employee's Date of Termination; provided that any applicable Age Discrimination in Employment Act, as amended, 29 U.S.C. Section 621 et seq., timing requirements will be set forth in the release.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Section 5. <u>Termination of Employment Due to Voluntary Resignation; Termination for Cause; Death; Long-Term Disability</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Voluntary Resignation or Termination for Cause</u>. In the event of the Employee's Voluntary Resignation or termination of his employment by the Company for Cause, the Employee shall not be entitled to any compensation, benefits, awards or other payments in connection with such termination of his employment, except as provided in <u>Section 4(a)</u> above. To terminate the Employee for Cause, the Company shall deliver to the Employee a written notice setting forth a summary of the material facts and/or circumstances that constitute Cause, in which event the termination will be effective as of the delivery of such notice.

4934-1749-1580.1

------

&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Death or Long-Term Disability</u>. In the event of the Employee's termination due to his death or Long-Term Disability, the Employee (or his estate or personal representative) shall be entitled to receive the amounts described in <u>Section 4(a)</u>. In the event of such a termination, the Employee shall not be treated as having incurred a COC Involuntary Termination or an Involuntary Termination and thus shall not be entitled to receive the severance benefits described herein.

&nbsp;&nbsp;&nbsp;&nbsp;**Section 6. <u>Termination of Employment Following COC.</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>COC Involuntary Termination</u>. In the event the Employee's employment is terminated under circumstances constituting a COC Involuntary Termination, the Employee shall be entitled to receive:

&nbsp;&nbsp;&nbsp;&nbsp;(i) the Employee's Accrued Compensation; and

&nbsp;&nbsp;&nbsp;&nbsp;(ii) an amount equal to six (6) months of Employee's Base Salary, net of applicable tax withholdings, payable in twelve (12) equal installments over a six-month period beginning on the first payroll date that occurs at least seven (7) days after timely execution and delivery by the Employee of the Release.

&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>COC Involuntary Termination - Effect on RSUs and RSAs</u>. If a COC Involuntary Termination of the Employee's employment occurs, vesting of any and all unvested restricted stock units ("***RSUs***") and restricted stock awards ("***RSAs***") granted to the Employee under the Company's 2024 Omnibus Incentive Plan or under any other equity plan of the Company shall be accelerated so that all such unvested RSUs and RSAs then held by the Employee shall be fully vested immediately upon the COC Involuntary Termination.

**Section 7. <u>Termination of Employment Due to Involuntary Termination (Not in Connection with COC).</u>** 

&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Involuntary Termination</u>. In the event the Employee's employment is terminated under circumstances constituting an Involuntary Termination (other than a COC Involuntary Termination), the Employee shall be entitled to receive:

&nbsp;&nbsp;&nbsp;&nbsp;(i) within fifteen (15) calendar days after the Date of Termination, the Employee's Accrued Compensation through the Date of Termination; and

&nbsp;&nbsp;&nbsp;&nbsp;(ii) an amount equal to six (6) months of Employee's Base Salary, net of applicable tax withholdings, payable in twelve (12) equal installments over a six-month period beginning on the first payroll date that occurs at least seven (7) days after timely execution and delivery by the Employee of the Release.

&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Effect on Options, Restricted Stock Units and Performance Stock Units</u>. In the case of an Involuntary Termination other than a COC Involuntary Termination, any unvested RSUs and RSAs shall be forfeited on the Date of Termination unless provided otherwise in the plan or award agreement governing such RSUs or RSAs.

&nbsp;&nbsp;&nbsp;&nbsp;**Section 8. <u>Successors</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) This Agreement is personal to the Employee, and, without the prior written consent of the Company, shall not be assignable by the Employee other than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Employee's legal representatives.

&nbsp;&nbsp;&nbsp;&nbsp;(b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Section 9. <u>Miscellaneous</u>.**

&nbsp;&nbsp;&nbsp;&nbsp;(a) The captions of this Agreement are not part of the provisions hereof and shall have no force or effect. This Agreement constitutes the entire agreement and understanding of the parties in respect of the subject matter hereof and supersedes all prior understanding, agreements, or representations by or among the parties, written or oral, to the extent they relate in any away to the subject matter hereof; *provided, however*, this Agreement shall have no effect on any confidentiality or restrictive covenant agreements or assignment of inventions agreements between the parties or on any legally required clawback policy of the Company's. This Agreement may not be amended or modified other than by a written agreement executed by the parties hereto or their respective successors and legal

4934-1749-1580.1

------

representatives. **Any prior executive change of control severance agreement (if any) or severance agreement (if any) between the Company (or its affiliates) and the Employee shall be deemed terminated upon the signing of this Agreement.** 

&nbsp;&nbsp;&nbsp;&nbsp;(b) All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if to the Employee, to the home address set forth in the Company's human resources files;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;if to the Company:

&nbsp;&nbsp;&nbsp;&nbsp;420 South Congress Avenue

&nbsp;&nbsp;&nbsp;&nbsp;Delray Beach, Florida 33445

&nbsp;&nbsp;&nbsp;&nbsp;Attention: General Counsel

or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee.

&nbsp;&nbsp;&nbsp;&nbsp;(c) The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(d) The Company may withhold from any amounts payable under this Agreement such United States federal, state or applicable local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation.

&nbsp;&nbsp;&nbsp;&nbsp;(e) The Employee's or the Company's failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Employee or the Company may have hereunder shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;(f) The Company may discontinue making payments under Section 6(a)(ii) or Section 7(a)(ii) of this Agreement in the event of a material breach by the Employee of any agreement between the Employee and the Company or any policy of the Company, including without limitation any material breach of the Employee's Non-Disclosure, Non-Solicitation, Non-Compete and Work for Hire Agreement with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(g) This Agreement shall be governed by the laws of the State of Florida, without giving effect to any choice of law provision or rule (whether of the State of Florida or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of Florida. All disputes arising under or related to this Agreement shall be resolved exclusively in the state or federal courts located in Palm Beach County, Florida.

*[Signature Page Follows]*

&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the parties have executed this Change of Control and General Severance Agreement as of the Effective Date.

---

| | |
|:---|:---|
| **PETMED EXPRESS, INC. <br>(the "Company")** | **PETMED EXPRESS, INC. <br>(the "Company")** |
| By: | /s/ Leslie CG Campbell |
|  | Leslie CG Campbell, Interim Chief Executive Officer and President |

---

4934-1749-1580.1

------

---

| | |
|:---|:---|
| **DOUGLAS KRULIK<br>(the "Employee")** | **DOUGLAS KRULIK<br>(the "Employee")** |
| By: | /s/ Douglas Krulik |
|  | Douglas Krulik, individually |

---

4934-1749-1580.1

------

ANNEX A

DEFINITIONS

&nbsp;&nbsp;&nbsp;&nbsp;(a) "***Accrued Compensation***" means an amount including all amounts earned or accrued through the Date of Termination but not paid as of the Date of Termination including (i) Base Salary, (ii) reimbursement for reasonable and necessary expenses incurred by the Employee on behalf of the Company during the period ending on the Date of Termination in accordance with the expense reimbursement policies of the Company, and (iii) vacation and sick leave pay (to the extent provided by Company policy or applicable law).

&nbsp;&nbsp;&nbsp;&nbsp;(b) "***Affiliate***" has the meaning ascribed to such term in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which shall include without limitation any subsidiary of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;(c) "***Applicable Benefit Plan***" means any written employee benefit plan in effect and in which the Employee participates or under which the Employee retains rights to benefits as of the time of the termination of his employment.

&nbsp;&nbsp;&nbsp;&nbsp;(d) "***Base Salary***" means the Employee's annual base salary at the rate in effect during the last regularly scheduled payroll period immediately preceding the occurrence of the termination of employment (disregarding any reduction in base salary that constitutes Good Reason) and does not include, for example, bonuses, overtime compensation, incentive pay, fringe benefits, sales commissions or expense allowances.

&nbsp;&nbsp;&nbsp;&nbsp;(e) "***Cause***" means any of the following: (i) commission of a willful act of dishonesty in the course of the Employee's duties or misappropriation of funds, theft, or embezzlement by the Employee of funds or property of Company or any Affiliate, (ii) engaging in conduct which in the reasonable determination of the Board constitutes a crime consisting of a felony, or conviction of the Employee, or the Employee's plea of no contest to, any criminal act involving a felony or fraud, dishonesty or moral turpitude, (iii) the Employee's engagement in dishonesty, illegal or disloyal conduct, personal misconduct, or willful or grossly negligent conduct, which is, in any such case, injurious to the interests, reputation or business of Company or its Affiliates as determined by the Board, (iv) Employee's performance under the influence of controlled substances (other than those taken pursuant to a medical doctor's orders), or continued habitual intoxication during working hours, (v) frequent or extended, and unjustifiable, absenteeism, (vi) the Employee's refusal or material failure to timely perform his duties and responsibilities or to timely carry out the lawful directives of Company or any Affiliates, or (vii) the Employee's material non-compliance with the terms of this Agreement or any policy of Company or any Affiliate.

&nbsp;&nbsp;&nbsp;&nbsp;(f) "***Change of Control***" shall have the meaning set forth in the PetMed Express, Inc. 2024 Omnibus Incentive Plan.

&nbsp;&nbsp;&nbsp;&nbsp;(g) "***COC Involuntary Termination***" means the termination of the Employee's employment with the Company at the time of or following a Change of Control before the end of the COC Period:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) by the Company without Cause, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) by the Employee for Good Reason.

&nbsp;&nbsp;&nbsp;&nbsp;(h) "***COC Period***" means the twelve (12) month period beginning on the date on which a Change of Control occurs.

&nbsp;&nbsp;&nbsp;&nbsp;(i) "***Date of Termination***" means (i) if the Employee's employment is terminated for Cause, the date of receipt by the Employee of written notice from Board or the Chief Employee Officer that the Employee has been terminated, or any later date specified therein, as the case may be, (ii) if the Employee's employment is terminated by the Company other than for Cause, death or Long-Term Disability, the date specified in the Company's written notice to the Employee of such termination, (iii) if the Employee's employment is terminated by reason of the Employee's death or Long-Term Disability, the date of such death or the effective date of such Long-Term Disability, and (iv) if the Employee's employment is terminated by Employee's resignation that constitutes Good Reason under this Agreement, the date of the Company's receipt of the Employee's notice of termination or any later date specified therein, which date shall not exceed thirty (30) days from the date notice is given.

&nbsp;&nbsp;&nbsp;&nbsp;(j) "***Good Reason***" means any of the following that occurs during the COC Period:

4934-1749-1580.1

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) without the Employee's express written consent a material reduction in the Employee's duties, level of responsibility, authority as the Company's principal accounting officer, <u>provided</u>, <u>however</u>, that the Company's employment of a new principal financial officer (and the Employee's cessation as the Company's Interim Principal Financial Officer), as well as the change in the Employee's reporting lines such that he will report to the new principal financial officer, shall not be deemed to be "Good Reason" hereunder; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) a material reduction in the Employee's Base Salary, without the Employee's express written consent, other than pursuant to a Company-wide reduction of base salaries and/or bonuses.

Notwithstanding the foregoing, the Employee will not be considered to have terminated for Good Reason unless (A) the Employee provides written notice to the Company of the circumstance(s) constituting the Good Reason event within 30 days following the initial existence of such event, (B) the Company fails to cure the Good Reason event within 30 days following its receipt of such notice, and (C) the Employee provides written notice to the Company of his Date of Termination.

&nbsp;&nbsp;&nbsp;&nbsp;(k) "***Involuntary Termination***" means the termination of Employee's employment with the Company at any time without Cause.

&nbsp;&nbsp;&nbsp;&nbsp;(l) "***Long-Term Disability***" means a determination made by the Company in good faith that that due to a mental or physical condition, the Employee has been unable and failed to substantially render his employment duties to the Company for a period of at least (x) 180 days out of any consecutive 360 days or (y) 90 consecutive days.

&nbsp;&nbsp;&nbsp;&nbsp;(m) "***Voluntary Resignation***" means the termination of the Employee's employment upon his voluntary resignation, which includes retirement. If the Employee terminates his employment for Good Reason, such termination shall not be treated as a Voluntary Resignation.

4934-1749-1580.1

## Exhibit 99.1

**PetMeds Extends Existing Shareholder Rights Plan**

DELRAY BEACH, Fla., November 26, 2025 – PetMed Express, Inc., d/b/a PetMeds and parent company of PetCareRx, (Nasdaq: PETS) (the "Company"), today announced that its Board of Directors (the "Board") has unanimously approved an amendment to the Company's existing shareholder rights plan (the "Rights Plan"), pursuant to which the expiration date of the Rights was extended for one year from the close of business on December 2, 2025 until the close of business on December 2, 2026. All other terms and conditions of the Rights Plan remain unchanged.

The Board adopted the Rights Plan to protect the investment of shareholders during a period in which it believes shares of the Company do not reflect the inherent value of the business or its long-term growth potential, and during which there have been recent significant accumulations of Company common stock by certain shareholders. In adopting the extension of the Rights Plan, the Board reiterated its belief that shares of the Company continue to not reflect the inherent value of the business or its long-term growth potential and that the Company remains vulnerable to the acquisition of actual or *de facto* control by one or more shareholders without paying a control premium to other shareholders.

The Rights Plan is not intended to interfere with any sale, merger, tender, exchange offer, or other business combination approved by the Board. Nor does the Rights Plan prevent the Board from considering any offer that recognizes the full value of PetMeds and is in the best interests of PetMeds' shareholders. Rather, the Rights Plan is intended to enable the Company's shareholders to realize the long-term value of their investment, ensure that all shareholders receive fair and equal treatment in the event of any proposed takeover of the Company, and to guard against tactics to gain control of the Company without paying all shareholders an appropriate premium for that control.

The amendment to the Rights Plan extends the expiration date of the Rights by one year. Unless earlier redeemed, terminated, or exchanged pursuant to the Rights Plan, the Rights will expire at the close of business on December 2, 2026.

Further details about the amendment to the Rights Plan will be contained in a Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (the "SEC").

**About PetMed Express, Inc.**

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit <u>www.PetMeds.com</u> and <u>www.PetCareRx.com</u>.

**Forward-Looking Statements**

4937-6494-8604.2

------

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. Words such as "may," "could," "expect," "project," "outlook," "strategy," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "strive," "goal," "continue," "likely," "will," "would" and other similar words and expressions are intended to signify forward-looking statements. These forward-looking statements include, without limitation, all statements related to the benefits of the Rights Plan and the ability of the Rights Plan to maximize shareholder value in the event of a takeover of the Company. Forward-looking statements are based on the Company's current expectations and assumptions regarding future events, which are subject to risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors, including but not limited to, the results of the now completed investigation by the Audit Committee of the Company's Board of Directors, the risk that the completion of the filing of the Company's Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and September 30, 2025 may take longer than expected, and other risks described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2025, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release and should not be relied upon as representing the Company's views as of any subsequent date. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.

**Investor Contact**

ICR, LLC

Reed Anderson

(646) 277-1260

<u>investor@petmeds.com</u>

4937-6494-8604.2